RxDoctor Payments Data

Monique Brown, MD

General Practice · Rocky Mount, NCNPI 1336289636

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 501 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,758in general payments, 2019–2025

Across 501 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Alkermes, Inc.$962
  • Otsuka America Pharmaceutical, Inc.$872
  • Neurocrine Biosciences, Inc.$724
  • Sunovion Pharmaceuticals Inc.$598
  • plus $4K from 26 others

What the payments were for

  • Food & beverage$9,758100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,758 in reported general payments places this provider in the 95th percentile of 2,924 general practice providers in North Carolina.

See all general practice providers in North Carolina

Medicare billing

Part B allowed, 2024
$25,902
Medicare patients
41
Services billed
476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine21$229,029
IngrezzaValbenazine Tosylate20$194,282
RexultiBrexpiprazole49$75,472
Invega SustennaPaliperidone Palmitate17$64,435
Abilify MaintenaAripiprazole16$44,531
AristadaAripiprazole Lauroxil13$39,817
VraylarCariprazine Hcl11$26,484
LinzessLinaclotide28$17,738
TrulicityDulaglutide18$17,177
FarxigaDapagliflozin Propanediol21$12,106
BelsomraSuvorexant23$10,871
VyvanseLisdexamfetamine Dimesylate14$5,876
Atomoxetine Hcl74$5,209
JanumetSitagliptin Phos/Metformin Hcl12$3,527
Paliperidone ErPaliperidone29$3,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,173$229,02921 claims
Neurocrine Biosciences, Inc.Ingrezza$724$194,28220 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$872$120,00365 claims
Johnson & JohnsonInvega Sustenna$251$64,43517 claims
AbbVieVraylar, Linzess$1,476$44,22239 claims
Alkermes, Inc.Aristada$962$39,81713 claims
Lilly USA, LLCTrulicity$43$17,17718 claims
AstraZenecaFarxiga$188$12,10621 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$69$5,87614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,924 general practice providers in North Carolina.

Other general practice in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →